Absence of cardiac valve dysfunction in obese patients treated with sibutramine

Obesity Research

Volumn 7, Issue 4, 1999, Pages 363-369

  Bach, David S ^a   Rissanen, Aila M ^b   Mendel, Carl M ^c   Shepherd, Gillian ^c   Weinstein, Steven P ^c   Kelly, Finian ^c   Seaton, Timothy B ^c   Patel, Bababhai ^c   Pekkarinen, Tmila A ^b   Armstrong, William F ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ABBOTT LABORATORIES   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anti obesity drugs; Aortic valve insufficiency; Echocardiography; Heart valves; Mitral valve insufficiency

Indexed keywords

ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE; SIBUTRAMINE;

ADULT; AGED; AORTA VALVE REGURGITATION; ARTICLE; BODY MASS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MITRAL VALVE REGURGITATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; BODY MASS INDEX; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; OBESITY; PREVALENCE;

EID: 0033160668     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1550-8528.1999.tb00419.x     Document Type: Article

References (6)

1. Conolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-8.
2. Centers for Disease Control. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR. 1997;46:1061-6.
3. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med, 1998;339:719-24.
4. Khan MA, Herzog CA, St. Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. W Engl J Med, 1998;339:713-8.
5. Weissman NJ, Tighe JF Jr., Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med, 1998;339:725-32.
6. Reid CL, Gardin JM, Yuna C, Kurosaki T, Flack JM, for the Coronary Artery Risk Development in Young Adults Research Group, University of California, Irvine, Orange, CA. Prevalence and clinical correlates of aortic and mitral regurgitation in a young adult population: the CARDIA study. Circulation. 1994;90:1-282.